Activity Dates: 04/18/2023 - 04/18/2026
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Treatment of opioid use disorder may include buprenorphine. A limitation of buprenorphine use is that patients must abstain from opioid use for some time prior to initiation therapy to avoid severe, precipitated withdrawal. There are some clinical situations where buprenorphine initiation is not successful. This can include prior unsuccessful initiations, use of illicit fentanyl, and transitioning from methadone. Buprenorphine micro-dosing (low dose) is an initiation strategy that can be utilized in these situations.
To receive ACPE credit for this session, you must:
Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Michael A. Smith, PharmD, FCCP, BCPS
View biographical information
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
2023 Program Committee and Recertification Editorial Board
 Elayne D. Ansara, PharmD, BCPP, BCPSProgram Committee Chair Clinical Pharmacy Specialist Veteran Health Indiana Indianapolis, IN No Relevant Financial Relationships to Disclose |
 Jolene R. Bostwick, PharmD, BCPP, BCPSProgram Administrative Chair Assistant Dean for Co-Curriculum and Professional Development & Clinical Professor University of Michigan College of Pharmacy Ann Arbor, MI No Relevant Financial Relationships to Disclose |
Bridget Bradley, PharmD, BCPP |
Austin R. Campbell, PharmD, BCPP |
|
Chelsea N. Carr, PharmD, BCPP Advanced Practice Pharmacist - Psychiatry University of Maryland School of Pharmacy Catonsville, MD No Relevant Financial Relationships to Disclose |
|
Dana Chiulli, PharmD, BCPP Clinical Pharmacist - Mental Health VISN 06 Mental Health Clinical Resource Hub Savannah, GA No Relevant Financial Relationships to Disclose |
|
Jordan Cooler Haygood, PharmD, BCPP Clinical Assistant Professor University of South Carolina College of Pharmacy Columbia, SC No Relevant Financial Relationships to Disclose |
|
Marissa Cullen, PharmD, BCPP Clinical Pharmacist UPMC Western Psychiatric Hospital Pittsburgh, PA No Relevant Financial Relationships to Disclose |
 Beth DeJongh, PharmD, BCPP, BCPSRecertification Editorial Board Chair Pharmacist Concordia University Wisconsin Mequon, WI No Relevant Financial Relationships to Disclose |
Bennett J. Doughty, PharmD, BCPP, BCPS |
|
Traci M. Dutton, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health; Program Director - PGY2 Psychiatric Pharmacy Residency VA Tennessee Valley Healthcare System Murfreesboro, TN External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Member of VA PBM Educational Advisory Committee which oversees Board Certification Study Groups |
 Megan J. Ehret, PharmD, BCPP, MS |
|
Kimberly Ehrhard, PharmD Clinical Pharmacist, Psychiatry The University of Kansas Health System Kansas City , KS No Relevant Financial Relationships to Disclose |
|
Michelle L. Geier, PharmD, BCPP Psychiatric Clinical Pharmacist Supervisor San Francisco Department of Public Health San Francisco, CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Weitzman Institute Project ECHO Faculty |
|
Abigail Hampton, PharmD, BCPP Psychiatric Clinical Pharmacist - Ambulatory University of Kansas Health System Kansas City, KS No Relevant Financial Relationships to Disclose |
|
Courtney A. Iuppa, PharmD, BCPP Clinical Pharmacy Manager & Residency Program Director Center for Behavioral Medicine Kansas City, MO No Relevant Financial Relationships to Disclose |
|
Archana R. Jhawar, PharmD, BCPP Clinical Pharmacist Jesse Brown VAMC/ UIC College of Pharmacy Chicago, IL No Relevant Financial Relationships to Disclose |
|
Kayla D. Johnson, PharmD, BCPP, BCPS Vanderbilt University Medical Center Thompsons Station, TN No Relevant Financial Relationships to Disclose |
|
Farah E. Khorassani, PharmD, BCPP Associate Clinical Professor St. John's University Queens, NY External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Consultant- Alkermes (Sept 2021) |
|
Dongmi Kim, PharmD, BCPP, BCPS Assistant Clinical Professor Fairleigh Dickinson University School of Pharmacy Florham Park, NJ No Relevant Financial Relationships to Disclose |
|
Jamie C. Kneebusch, PharmD, BCPP, BCPS Assistant Clinical Faculty UC San Diego, Skaggs School of Pharmacy La Jolla, CA No Relevant Financial Relationships to Disclose |
|
Erin D. Knox, PharmD, BCPP Director of Experiential Education UCI School of Pharmacy & Pharmaceutical Sciences Irvine, CA Non-Financial Interests: Santa Ana Community College, Pharmacy Technology Program, Advisory Committee |
|
Lauren E. Leiby, PharmD, BCPP Behavioral Health Patient Care Pharmacist Nationwide Childrens Hospital Columbus, OH No Relevant Financial Relationships to Disclose |
|
Amber R. Lemons, PharmD, BCPP Behavioral Health Pharmacist Denver Health Medical Center Denver, CO No Relevant Financial Relationships to Disclose |
|
Linda D. Logan, PharmD, BCACP, BCPP, BCPS Public Service Associate University of Georgia Athens, GA Educational Grants, Research Grants or Contracts: HRSA Graduate Psychology Education Grant, CPNP Foundation Student Grant (Advisor), UGA College Pharmacy Ansel Fund |
|
Monica Mathys, PharmD, BCGP, BCPP Professor Texas Tech University School of Pharmacy Dallas, TX Non-Financial Interests: CPNP Foundation Board member |
Lindsey N. Miller, PharmD, BCPP |
|
Melissa Mitchell, PharmD, BCGP, BCPP, BCPS Assistant Director of Pharmacy;Residency Program Director RUHS Medical Center Moreno Valley , CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Neurocrine Speakers Bureau - Ingrezza, Janssen Speakers Bureau - Spravato, Otsuka - PsychU.org Speaker |
|
Thea R. Moore, PharmD, BCPP Associate Professor University of South Florida Tampa, FL No Relevant Financial Relationships to Disclose |
|
Jessica L. Mulhollan, PharmD, BCPP Clinical Pharmacy Specialist, Substance Use Disorders and Mental Health Clinical Pharmacy Supervisor Louis Stokes Cleveland VA Medical Center Cleveland, OH No Relevant Financial Relationships to Disclose |
|
Kristen Neumeister, PharmD, BCPP Clinical Pharmacist- Mental Health John Peter Smith Hospital Fort Worth, TX No Relevant Financial Relationships to Disclose |
|
Megan O'Connell, PharmD, BCPP Advanced Practice Pharmacist - Psychiatry University of Maryland - Clifton T. Perkins Hospital jessup, MD No Relevant Financial Relationships to Disclose |
|
Melissa C. Palmer, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health Alaska VA Healthcare System Anchorage, AK No Relevant Financial Relationships to Disclose |
|
Haley Pals, PharmD, BCPP Substance Use Disorder/Psychiatric Clinical Pharmacist Tomah VA Medical Center Tomah, WI No Relevant Financial Relationships to Disclose |
|
Brittany L. Parmentier, PharmD, BCPS, BCPP Clinical Assistant Professor University of Texas at Tyler Tyler, TX No Relevant Financial Relationships to Disclose |
|
Jake R. Peters, PharmD, BCPP, BCPS Assistant Professor of Pharmacy Practice/Clinical Pharmacy Specialist - Psychiatry Butler University College of Pharmacy/Indiana University Health Indianapolis, IN No Relevant Financial Relationships to Disclose |
|
Lindsey Peters, PharmD, BCPS Associate Professor of Pharmacy Practice Ohio Northern University Ada, OH No Relevant Financial Relationships to Disclose |
|
Sarah J. Popish, PharmD, BCPP Academic Educator Department of Veterans Affairs Vallejo, CA No Relevant Financial Relationships to Disclose |
|
Nina Vadiei, PharmD, BCPP Assistant Professor University of Arizona Colleges of Pharmacy and Medicine Tucson, AZ No Relevant Financial Relationships to Disclose |
|
Heidi J. Wehring, PharmD, BCPP Adjunct Associate Professor of Psychiatry Maryland Psychiatric Research Center, University of Maryland School of Medicine Baltimore, MD No Relevant Financial Relationships to Disclose |
|
Kara R. Wong, PharmD, BCPP Clinical Pharmacy Specialist, Mental Health; PGY2 Psychiatric Pharmacy Residency Program Director Minneapolis VA Health Care System Minneapolis, MN No Relevant Financial Relationships to Disclose |
All relevant relationships have been mitigated.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: microgram buprenorphine
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.